Global market sentiment in developed economies is starting to firm, which can draw more attention to long term themes rather than short term fear. That puts Transformative AI Healthcare stocks back in focus for investors who do not want to miss the next big shift in how care is delivered. This article walks through 3 stocks from the screener that show how this theme is playing out in practice.
The three stocks below are just a starting sample from this Transformative AI Healthcare theme, and the full screen surfaced 4 more companies with equally compelling narratives that are not covered in the article. If you want to identify your own highest conviction ideas in this space, go straight to the Transformative Artificial intelligence (AI) Healthcare Stocks screener to filter and analyze the wider opportunity set.
Profound Medical (TSX:PRN)
Overview: Profound Medical is a commercial-stage medical device company that uses AI-powered, MRI-guided systems like its TULSA-PRO platform to precisely ablate prostate tissue without incisions, and Sonalleve for MR-guided thermal treatment of fibroids, pain from bone metastases, and other benign tumors. The strongest link to the AI healthcare theme is TULSA-PRO, which combines MRI imaging, robotic ultrasound delivery, and closed-loop temperature feedback so software can help clinicians target and control treatment in real time.
Operations: Profound Medical generates all of its approximately $19 million in revenue from medical technology, primarily in the U.S. at about $12 million, with Canada contributing around $6 million and Germany less than $1 million.
Market Cap: CA$344 million
Profound Medical provides direct exposure to AI-guided therapy in prostate cancer, with its TULSA-PRO system using MRI, robotic control and real-time temperature feedback to support highly targeted ablation that seeks to preserve quality of life compared with traditional surgery. Recent software upgrades that add real-time iMRI control and supervised robotic autonomy underline the central role of AI-enabled image processing and decision support in the product story. At the same time, the company is still loss making, relies on external funding and has seen shareholder dilution, so the market is already weighing meaningful execution and financing risk. For investors willing to focus on long term AI-driven treatment shifts, this mix of growing adoption signals and unresolved profitability questions may justify deeper research.
Profound Medical’s AI guided therapy story is growing more visible, yet the market is still wrestling with losses and funding needs. For the full context, see the 1 key reward and 1 important warning sign
Healwell AI (TSX:AIDX)
Overview: Healwell AI is a Toronto based healthcare technology company that builds AI driven clinical decision support tools and screening engines that help providers, insurers and public health groups detect rare and chronic diseases, tightly integrated with its electronic health record and data interoperability software across Canada, Australia and New Zealand. Alongside these AI decision support products, it also runs broader healthcare software platforms and contract research services that contribute to revenue but are less central to the Transformative AI Healthcare theme.
Operations: Healwell AI generates most of its approximately CA$128.7 million in revenue from Healthcare Software at about CA$119.1 million, with around CA$9.6 million from AI and Data Sciences, and around CA$110.4 million of total revenue coming from Australia and New Zealand and CA$18.4 million from Canada.
Market Cap: CA$231.5 million
Healwell AI gives you direct exposure to AI tools that aim to make clinicians faster and more accurate rather than replacing them, with disease screening engines and ASI co‑pilot tools built into everyday EHR workflows so they can scale across hospitals, clinics and insurers. The Orion acquisition and integration with Verosource, IntraHealth and Pentavere mean the company now controls a large health data and software footprint, which could be valuable as healthcare systems push for interoperable, AI ready records. At the same time, Healwell AI is still in a business model transition, leans on acquisitions and external funding, and is not expected to reach clear, sustained profitability in the near term. For investors who want AI in healthcare diagnostics and decision support at the company level rather than only in big tech, that mix of growing data reach, improving earnings signals and execution risk makes Healwell AI worth a closer look.
Healwell AI’s expanding data footprint and EHR reach could be masking the real turning point in its business model. Get the full story in the analysis report for Healwell AI
Perimeter Medical Imaging AI (TSXV:PINK)
Overview: Perimeter Medical Imaging AI develops imaging systems that give surgeons real time, cross sectional views of excised tissue in the operating room. Its Claire OCT platform uses ImgAssist artificial intelligence to help assess cancer margins during breast conserving surgery. The company also supplies its S Series OCT system, a proprietary image library and consumable specimen containers to hospitals and cancer surgery centers.
Operations: Perimeter Medical Imaging AI generates about $2.1 million in revenue from Medical Imaging Systems, all currently reported from Canada.
Market Cap: CA$40.7 million
Perimeter Medical Imaging AI may be of interest if you care about AI that directly supports surgeons at the point of care. Its Claire OCT system with ImgAssist uses machine learning to flag suspicious tissue during breast cancer surgery and is now being deployed across Intermountain Health, which illustrates how this technology can move from pilot to system wide use. At the same time, the company is still early stage, with around $2 million in revenue and reported losses in the first half of 2026, so investors face clear funding and dilution risk. If AI guided imaging becomes embedded in standard surgical workflows, that small base and focused product set could have a significant impact on how the business develops.
Surgeon level AI support is starting to scale, yet Perimeter Medical Imaging AI still trades like a tiny pilot project. Get the 2 key rewards and 3 important warning signs (1 is major!) and see what the current numbers might be hinting at
Seeking Fresh Alternatives For Your Watchlist
Fresh stock ideas can move from quiet accumulation to breakout momentum quickly. Scan these curated lists before the crowd, while the data still matters, and consider getting in early.
- Target companies aiming for strong cash generation and robust balance sheets with the curated 12 high quality undervalued stocks before potential interest sends attention flying their way.
- Zero in on lesser known businesses where quality metrics still look under the radar for now with the focused 9 high quality undiscovered gems and reduce the risk of getting caught chasing later.
- Back test your income watchlist against a hand picked 4 dividend fortresses that could help you spot yields worth examining before payouts or prices start dropping.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com